PMID- 23450462
OWN - NLM
STAT- MEDLINE
DCOM- 20131105
LR  - 20130408
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 7
IP  - 5
DP  - 2013 May
TI  - The effect of telomerase activity on vascular smooth muscle cell proliferation in 
      type 2 diabetes in vivo and in vitro.
PG  - 1636-40
LID - 10.3892/mmr.2013.1350 [doi]
AB  - Serious complications as a result of type 2 diabetes mellitus (T2DM) are becoming 
      a major health concern. In the present study, it was hypothesized that telomerase 
      activity is upregulated in vascular smooth muscle cells (VSMCs) during 
      proliferation in T2DM and that the application of telomerase inhibitors impedes 
      the proliferation of VSMCs in vitro. Male Wistar rats were randomly allocated 
      into the normal control (NC) or diabetic (DM) group. Diabetes was induced by 
      high‑fat feeding and a low dose of streptozotocin (STZ; 30 mg/kg). Primary VSMC 
      cultures were exposed to normal (5.5 mM) or high (25 mM) glucose and insulin 
      (100 nM) in the presence and absence of various concentrations of antisense 
      oligoribonucleotides (ASODNs) for varying lengths of time. Telomerase activity 
      and the proliferation of VSMCs were measured. Results showed that there was a 
      significant increase in the levels of fasting glucose, insulin, triglycerides 
      (TG) and free fatty acids (FFAs) in the diabetic group. Telomerase activity and 
      the proliferation of VSMCs were significantly higher in the diabetic group 
      in vivo and in the high glucose and insulin (HGI)-treated group in vitro 
      (P<0.01). ASODNs significantly inhibited the proliferation of VSMCs in a 
      concentration- and time‑dependent manner (P<0.01). In conclusion, hyperglycemia 
      and hyperinsulinemia stimulate telomerase activity and the proliferation of 
      VSMCs, while the inhibition of telomerase activity reduces the proliferation of 
      VSMCs, indicating that telomerase may be involved in the pathological process of 
      diabetic vascular disease.
FAU - Sun, Xiaodong
AU  - Sun X
AD  - Department of Endocrinology, The Affiliated Hospital of Weifang Medical 
      University, Weifang, Shangdong 261031, PR China. sxdfriend@sina.com
FAU - Han, Fang
AU  - Han F
FAU - Yi, Junling
AU  - Yi J
FAU - Hou, Ningning
AU  - Hou N
FAU - Cao, Zhibin
AU  - Cao Z
LA  - eng
PT  - Journal Article
DEP - 20130228
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids)
RN  - 0 (Oligoribonucleotides)
RN  - 0 (Triglycerides)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - Cell Proliferation
MH  - Diabetes Mellitus, Experimental/blood/*enzymology/pathology
MH  - Diabetes Mellitus, Type 2/blood/*enzymology/*pathology
MH  - Fatty Acids/blood
MH  - Male
MH  - Muscle, Smooth, Vascular/*pathology
MH  - Myocytes, Smooth Muscle/*enzymology/*pathology
MH  - Oligoribonucleotides/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Telomerase/*metabolism
MH  - Triglycerides/blood
EDAT- 2013/03/02 06:00
MHDA- 2013/11/06 06:00
CRDT- 2013/03/02 06:00
PHST- 2012/10/28 00:00 [received]
PHST- 2013/02/12 00:00 [accepted]
PHST- 2013/03/02 06:00 [entrez]
PHST- 2013/03/02 06:00 [pubmed]
PHST- 2013/11/06 06:00 [medline]
AID - 10.3892/mmr.2013.1350 [doi]
PST - ppublish
SO  - Mol Med Rep. 2013 May;7(5):1636-40. doi: 10.3892/mmr.2013.1350. Epub 2013 Feb 28.